Bio-Connect

InVivoPlus anti-mouse PD-1 (CD279)

BP0033-2
Bio X Cell
ApplicationsWestern Blot, Neutralisation/Blocking
Product group Antibodies
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    Bio X Cell
  • Product Name
    InVivoPlus anti-mouse PD-1 (CD279)
  • Delivery Days Customer
    7
  • Applications
    Western Blot, Neutralisation/Blocking
  • Certification
    Research Use Only
  • Clonality
    Monoclonal
  • Clone ID
    J43
  • Concentration
    4-11 mg/ml
  • Estimated Purity
    >95%
  • Host
    Hamster
  • Isotype
    IgG
  • Storage Instruction
    2°C to 8°C
  • UNSPSC
    12352203

References

  • Li J, Lee Y, Li Y, et al. Co-inhibitory Molecule B7 Superfamily Member 1 Expressed by Tumor-Infiltrating Myeloid Cells Induces Dysfunction of Anti-tumor CD8(+) T Cells. Immunity. 2018,48(4):773-786.e5. doi: 10.1016/j.immuni.2018.03.018
    Read this paper
  • Imai Y, Ayithan N, Wu X, et al. Cutting Edge: PD-1 Regulates Imiquimod-Induced Psoriasiform Dermatitis through Inhibition of IL-17A Expression by Innate γδ-Low T Cells. J Immunol. 2015,195(2):421-5. doi: 10.4049/jimmunol.1500448
    Read this paper
  • Li C, Li W, Xiao J, et al. ADAP and SKAP55 deficiency suppresses PD-1 expression in CD8+ cytotoxic T lymphocytes for enhanced anti-tumor immunotherapy. EMBO Mol Med. 2015,7(6):754-69. doi: 10.15252/emmm.201404578
    Read this paper
  • Van der Jeught K, Joe PT, Bialkowski L, et al. Intratumoral administration of mRNA encoding a fusokine consisting of IFN-β and the ectodomain of the TGF-β receptor II potentiates antitumor immunity. Oncotarget. 2014,5(20):10100-13.
    Read this paper
  • Verhagen J, Wraith DC. Blockade of LFA-1 augments in vitro differentiation of antigen-induced Foxp3⁺ Treg cells. J Immunol Methods. 2014,414:58-64. doi: 10.1016/j.jim.2014.07.012
    Read this paper
  • Sarraj B, Ye J, Akl AI, et al. Impaired selectin-dependent leukocyte recruitment induces T-cell exhaustion and prevents chronic allograft vasculopathy and rejection. Proc Natl Acad Sci U S A. 2014,111(33):12145-50. doi: 10.1073/pnas.1303676111
    Read this paper
  • Rabenstein H, Behrendt AC, Ellwart JW, et al. Differential kinetics of antigen dependency of CD4+ and CD8+ T cells. J Immunol. 2014,192(8):3507-17. doi: 10.4049/jimmunol.1302725
    Read this paper
  • Park SJ, Namkoong H, Doh J, et al. Negative role of inducible PD-1 on survival of activated dendritic cells. J Leukoc Biol. 2014,95(4):621-9. doi: 10.1189/jlb.0813443
    Read this paper
  • Schwager K, Hemmerle T, Aebischer D, et al. The immunocytokine L19-IL2 eradicates cancer when used in combination with CTLA-4 blockade or with L19-TNF. J Invest Dermatol. 2013,133(3):751-758. doi: 10.1038/jid.2012.376
    Read this paper
  • Noval Rivas M, Weatherly K, Hazzan M, et al. Reviving function in CD4+ T cells adapted to persistent systemic antigen. J Immunol. 2009,183(7):4284-91. doi: 10.4049/jimmunol.0901408
    Read this paper